Group One Trading’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-1,000
Closed -$4.47K – 8536
2026
Q1
$4.47K Sell
1,000
-188,400
-99% -$876K ﹤0.01% 6752
2025
Q4
$1.04M Buy
189,400
+186,400
+6,213% +$905K ﹤0.01% 2848
2025
Q3
$9.8K Hold
3,000
– – ﹤0.01% 7182
2025
Q2
$6.93K Buy
+3,000
New +$6.52K ﹤0.01% 6934
2024
Q4
– Sell
-400
Closed -$804 – 7985
2024
Q3
$804 Sell
400
-2,000
-83% -$4.39K ﹤0.01% 6322
2024
Q2
$5.38K Sell
2,400
-500
-17% -$1.46K ﹤0.01% 5918
2024
Q1
$8.32K Buy
+2,900
New +$6.04K ﹤0.01% 5965
2023
Q2
– Sell
-4,000
Closed -$3.19K – 8232
2023
Q1
$3.19K Hold
4,000
– – ﹤0.01% 6476
2022
Q4
$9.04K Buy
+4,000
New +$8.1K ﹤0.01% 6069

Other funds holding TSHA

Group One Trading's TSHA Position: Q3 2026 in Review

Group One Trading increased its Taysha Gene Therapies (TSHA) stake by 3.5% in Q3 2026, buying an estimated $386 and bringing the position to 2,006 shares worth $9.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6329.

Group One Trading first reported a position in TSHA in Q4 2022 and has held it in 8 quarters since. The position peaked at $243K in Q4 2025. 205 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Group One Trading held 2,006 shares of Taysha Gene Therapies worth $9.8K as of Q3 2026.
  • Group One Trading bought 67 Taysha Gene Therapies shares in Q3 2026, an estimated $386.
  • Taysha Gene Therapies made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #6329 holding.
  • Group One Trading first reported a position in Taysha Gene Therapies in Q4 2022 and has held it in 8 quarters since.
  • Group One Trading's Taysha Gene Therapies position peaked at $243K in Q4 2025.
  • 205 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.